Lucia Zhang

Lucia Zhang is a Canadian regulatory official based in Ottawa, Ontario. She is a Senior Clinical Evaluator at Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (BRDD).^{1) 2)}

Zhang's hometown is Edmonton, Alberta.³⁾

Zhang attended the University of Toronto from September 2009 to June 2013 for her Bachelor of Science in Pharmacology and Toxicology, and September 2013 to June 2018 for her Doctor of Philosophy in Pharmacology.⁴⁾ She worked as as Summer Intern at National Research Council Canada (NRC) from May to August 2010. She volunteered at Toronto Western Hospital from September 2012 to June 2013.

Zhang began work at Health Canada as a Clinical Evaluator in June 2018.

On February 2021, the journal Bioanalysis published a paper co-authored by Zhang titled 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 – Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays).⁵⁾ Among her co-authors are representatives from:

• AbbVie
• Ablynx
• AstraZeneca
• BioAgilytix
• Biogen
• BioMarin
• Bluebird Bio
• BRI
• Canadian Forum for Analytical and Bioanalytical Sciences (CFABS)
• CRISPR Therapeutics
• Food and Drug Administration (FDA)
• GlaxoSmithKline
• Hexal
• Immunologix Labs
• Intellia Therapeutics
• Janssen
• Medicines & Healthcare products Regulatory Agency (MHRA)
• Merck
• Ministry of Health, Labour and Welfare of Japan (MHLW)
• Navigate BioPharma
• Norwegian Medicines Agency
• Novartis
• Novo Nordisk
• Pfizer
• PPD
• Regeneron Pharmaceuticals
• Roche
• Sangamo Therapeutics
• Takeda

Zhang was promoted to Senior Clinical Evaluator in March 2021.

• LinkedIn